Healthcare - Biotechnology - NASDAQ - IT
$ 5.02
1.01 %
$ 91.8 M
Market Cap
-9.84
P/E
CASH FLOW STATEMENT
-11.2 M
OPERATING CASH FLOW
-14.9 M
INVESTING CASH FLOW
531
FINANCING CASH FLOW
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
Genenta Science S.p.A.
| Net Income | -11.6 M |
| Depreciation & Amortization | 42.5 K |
| Capital Expenditures | -13.8 K |
| Stock-Based Compensation | 740 K |
| Change in Working Capital | -418 K |
| Others | 386 K |
| Free Cash Flow | -11.2 M |
Cash Flow
Millions
| Dec-2023 | Dec-2022 | Dec-2021 | Dec-2020 | Dec-2019 | |
|---|---|---|---|---|---|
| OPERATING CASH FLOW | |||||
| Net Income | (11.6) | (8.5) | (5.5) | (5.6) | (4.6) |
| Depreciation & Amortization | 42.5 K | 6.14 K | 4.89 K | 1.9 K | 0 |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock Based Compensation | 0.7 | 0.7 | 0.5 | 0.5 | 0.7 |
| Other Operating Activities | 75.7 K | 90.4 K | 13.2 K | 6.06 K | 4.87 K |
| Change in Working Capital | (0.4) | 0.2 | (1.9) | (0.9) | 1.4 |
| Cash From Operations | (11.2) | (7.4) | (7.0) | (6.0) | (2.5) |
| INVESTING CASH FLOW | |||||
| Capital Expenditures | 13.8 K | 27.1 K | 9.01 K | 20.9 K | 0 |
| Other Items | (14.9) | 0 | 0 | 0 | 0 |
| Cash From Investing Activities | (14.9) | 27.1 K | 9.01 K | 20.9 K | 0 |
| FINANCING CASH FLOW | |||||
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Total Debt Repaid | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 0 | 0 | 543 | (0.1) | (0.3) |
| Cash From Financing Activities | 531 | 0 | 28.7 | 1.4 | 14.8 |
| CHANGE IN CASH | |||||
| Net Change In Cash | (26.1) | (7.4) | 21.8 | (4.7) | 12.3 |
| FREE CASH FLOW | |||||
| Free Cash Flow | (11.2) | (7.4) | (7.0) | (6.1) | (2.5) |